Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
作者信息
Lipshultz Steven E
机构信息
Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
出版信息
Circ Res. 2018 Mar 30;122(7):e62-e63. doi: 10.1161/CIRCRESAHA.118.312918.
Abstract
摘要
相似文献
1
Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
Circ Res. 2018 Mar 30;122(7):e62-e63. doi: 10.1161/CIRCRESAHA.118.312918.
2
Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
Circ Res. 2018 Mar 30;122(7):e64-e65. doi: 10.1161/CIRCRESAHA.118.312921.
3
Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?
Circ Res. 2018 Jan 19;122(2):188-190. doi: 10.1161/CIRCRESAHA.117.312395.
4
[Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Kardiologiia. 2016 Dec;56(12):72-79.
5
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Korean J Intern Med. 2016 Jul;31(4):625-33. doi: 10.3904/kjim.2016.017. Epub 2016 Jul 1.
6
Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology.
Toxicol Appl Pharmacol. 2023 Jan 15;459:116362. doi: 10.1016/j.taap.2022.116362. Epub 2022 Dec 30.
7
Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes.
Curr Opin Cardiol. 2019 May;34(3):289-295. doi: 10.1097/HCO.0000000000000617.
8
Genotyping the risk of anthracycline-induced cardiotoxicity.
Cardiovasc Toxicol. 2007;7(2):129-34. doi: 10.1007/s12012-007-0024-2.
9
Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84. doi: 10.3310/hta11270.
10
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.
Future Cardiol. 2015 Jul;11(4):363-6. doi: 10.2217/FCA.15.35. Epub 2015 Aug 4.
引用本文的文献
1
Cardio-oncology for Pediatric and Adolescent/Young Adult Patients.
Curr Treat Options Oncol. 2023 Aug;24(8):1052-1070. doi: 10.1007/s11864-023-01100-4. Epub 2023 Jun 10.
2
The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside.
Oxid Med Cell Longev. 2022 Sep 21;2022:3659278. doi: 10.1155/2022/3659278. eCollection 2022.
3
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.
Cardiooncology. 2019 Dec 2;5:18. doi: 10.1186/s40959-019-0054-5. eCollection 2019.
4
Cardiovascular diseases in survivors of childhood cancer.
Cancer Metastasis Rev. 2020 Mar;39(1):55-68. doi: 10.1007/s10555-020-09859-w.
本文引用的文献
1
Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?
Circ Res. 2018 Jan 19;122(2):188-190. doi: 10.1161/CIRCRESAHA.117.312395.
2
Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research.
Cardiovasc Res. 2018 Feb 1;114(2):205-209. doi: 10.1093/cvr/cvx246.
3
Molecular mechanism of doxorubicin-induced cardiomyopathy - An update.
Eur J Pharmacol. 2018 Jan 5;818:241-253. doi: 10.1016/j.ejphar.2017.10.043. Epub 2017 Oct 23.
4
Chemotherapy-induced cardiotoxicity in children.
Expert Opin Drug Metab Toxicol. 2017 Aug;13(8):817-832. doi: 10.1080/17425255.2017.1351547. Epub 2017 Jul 13.
5
Doxorubicin targets multiple players: A new view of an old problem.
Pharmacol Res. 2018 Jan;127:4-14. doi: 10.1016/j.phrs.2017.03.016. Epub 2017 Mar 20.
6
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Nat Med. 2016 May;22(5):547-56. doi: 10.1038/nm.4087. Epub 2016 Apr 18.
7
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.
Circulation. 2013 Oct 22;128(17):1927-95. doi: 10.1161/CIR.0b013e3182a88099. Epub 2013 Sep 30.
8
Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.
J Chemother. 2012 Oct;24(5):292-6. doi: 10.1179/1973947812Y.0000000038.
9
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
J Clin Oncol. 2012 Apr 1;30(10):1042-9. doi: 10.1200/JCO.2010.30.3404. Epub 2012 Feb 27.
10
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
J Korean Med Sci. 2010 Sep;25(9):1336-42. doi: 10.3346/jkms.2010.25.9.1336. Epub 2010 Aug 12.
Zotero 插件